We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
HIMS Partners With Lilly to Offer FDA-Approved Weight-Loss Drugs
Read MoreHide Full Article
Key Takeaways
HIMS partners with Eli Lilly to offer FDA-approved Zepbound and Foundayo through its digital health platform.
Self-pay prices start at $149 monthly for Foundayo and $299 for Zepbound, with home delivery available.
HIMS' expanded weight-loss portfolio could attract more patients, boost retention and long-term growth.
Hims & Hers Health, Inc. (HIMS - Free Report) has partnered with Eli Lilly and Company (LLY - Free Report) to expand patient access to Lilly’s FDA-approved obesity treatments, Zepbound and Foundayo, through its digital health platform. The agreement strengthens HIMS’ position in the growing weight-loss care market by adding established branded therapies to its treatment offerings.
From an investor perspective, the partnership could support HIMS’ long-term growth by enhancing its weight-loss platform, attracting more patients seeking FDA-approved treatments and strengthening its relationship with leading pharmaceutical companies. However, the extent to which the deal contributes to revenue growth and profitability will depend on patient adoption, prescription volumes and the economics of the arrangement.
HIMS Stock Trend
Year to date, the stock plunged 39.3%, underperforming the industry’s 21.6% growth and the S&P 500’s 10.2% gain.
The partnership with Eli Lilly could support Hims & Hers' long-term growth by expanding its access to established, FDA-approved obesity treatments and strengthening its competitive positioning in the rapidly growing weight-loss market. Offering branded GLP-1 medicines could help HIMS attract a broader patient base, improve customer acquisition and retention, and deepen engagement across its digital health platform. Additionally, the collaboration with a leading pharmaceutical company enhances HIMS' credibility as a provider of weight-management care and could create opportunities to build a more comprehensive, recurring-revenue business.
Over time, higher patient volumes and sustained demand for branded obesity treatments could support revenue growth, although the financial contribution will depend on prescription uptake and the economics of the partnership.
HIMS currently has a market capitalization of $4.86 billion.
Image Source: Zacks Investment Research
More on the News
Under the agreement, eligible patients can access Lilly's Zepbound (tirzepatide) and Foundayo (orforglipron) through the Hims & Hers platform after receiving a prescription from a licensed provider. The arrangement allows patients to complete consultations, obtain prescriptions when medically appropriate and have the medicines delivered directly to their homes without leaving the platform.
Self-pay prices start at $149 per month for Foundayo and $299 per month for Zepbound, matching the prices available to other self-pay patients. The addition of Foundayo, Lilly's daily oral obesity medicine, also broadens the range of branded weight-loss treatment options available to HIMS customers.
Hims & Hers' weight-loss membership also provides patients with 24/7 access to a care team, nutrition guidance, regular clinical check-ins and access to its weight-loss community. Its technology platform supports provider outreach, treatment planning and follow-up care, enabling the company to maintain engagement throughout the treatment journey.
Importantly, HIMS has confirmed that it has never offered compounded versions of Lilly's GLP-1 medicines and has committed not to do so in the future. Both companies have also agreed to protect independent clinical decision-making, ensuring that providers retain the authority to prescribe treatments they consider appropriate for individual patients. These commitments strengthen the framework for the collaboration while supporting access to FDA-approved medicines through HIMS' digital care platform.
Industry Prospects Favoring the Market
According to Grand View Research, the global obesity treatment market size was valued at $15.9 billion in 2024 and is projected to grow from $29 billion in 2026 to $60.5 billion by 2030, at a CAGR of 22.3%.
The industry is driven by several key factors, including the rising global prevalence of obesity and its associated comorbidities, such as diabetes, cardiovascular diseases, and hypertension.
Other News
Recently, Hims & Hers exited the third quarter of 2026 with lower-than-expected earnings and revenues. Nevertheless, the company recorded robust year-over-year revenue growth, supported by strong performances across its domestic and international businesses. The increase in subscribers and monthly revenue per average subscriber during the quarter was encouraging.
Per management, HIMS' international performance benefited from the Eucalyptus acquisition, while domestic revenue growth accelerated for the second consecutive quarter. The company's expanding weight loss portfolio, strategic collaborations with Novo Nordisk and Eli Lilly and continued investments in AI-driven technology are encouraging.
Some better-ranked stocks from the broader medical space are Glaukos (GKOS - Free Report) and Intuitive Surgical (ISRG - Free Report) .
Glaukos, currently flaunting a Zacks Rank #1 (Strong Buy), reported third-quarter 2026 adjusted earnings per share (EPS) of 47 cents, which surpassed the Zacks Consensus Estimate by 491.7%. Revenues of $211 million beat the Zacks Consensus Estimate by 25%. You can see the complete list of today’s Zacks #1 Rank stocks here.
GKOS has an estimated earnings growth rate of 155.6% for 2026. The company’s earnings beat estimates in three of the trailing four quarters and missed once, the average surprise being 138.6%.
Intuitive Surgical, currently carrying a Zacks Rank #2 (Buy), reported third-quarter 2026 adjusted EPS of $3.00, which beat the Zacks Consensus Estimate by 13.6%. Revenues of $3.05 billion surpassed the Zacks Consensus Estimate by 4.9%.
Intuitive Surgical has a long-term estimated growth rate of 15.5%. ISRG’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 15.1%.
View the Zacks #1 Rank List
Image: Bigstock
HIMS Partners With Lilly to Offer FDA-Approved Weight-Loss Drugs
Key Takeaways
Hims & Hers Health, Inc. (HIMS - Free Report) has partnered with Eli Lilly and Company (LLY - Free Report) to expand patient access to Lilly’s FDA-approved obesity treatments, Zepbound and Foundayo, through its digital health platform. The agreement strengthens HIMS’ position in the growing weight-loss care market by adding established branded therapies to its treatment offerings.
From an investor perspective, the partnership could support HIMS’ long-term growth by enhancing its weight-loss platform, attracting more patients seeking FDA-approved treatments and strengthening its relationship with leading pharmaceutical companies. However, the extent to which the deal contributes to revenue growth and profitability will depend on patient adoption, prescription volumes and the economics of the arrangement.
HIMS Stock Trend
Year to date, the stock plunged 39.3%, underperforming the industry’s 21.6% growth and the S&P 500’s 10.2% gain.
The partnership with Eli Lilly could support Hims & Hers' long-term growth by expanding its access to established, FDA-approved obesity treatments and strengthening its competitive positioning in the rapidly growing weight-loss market. Offering branded GLP-1 medicines could help HIMS attract a broader patient base, improve customer acquisition and retention, and deepen engagement across its digital health platform. Additionally, the collaboration with a leading pharmaceutical company enhances HIMS' credibility as a provider of weight-management care and could create opportunities to build a more comprehensive, recurring-revenue business.
Over time, higher patient volumes and sustained demand for branded obesity treatments could support revenue growth, although the financial contribution will depend on prescription uptake and the economics of the partnership.
HIMS currently has a market capitalization of $4.86 billion.
Image Source: Zacks Investment Research
More on the News
Under the agreement, eligible patients can access Lilly's Zepbound (tirzepatide) and Foundayo (orforglipron) through the Hims & Hers platform after receiving a prescription from a licensed provider. The arrangement allows patients to complete consultations, obtain prescriptions when medically appropriate and have the medicines delivered directly to their homes without leaving the platform.
Self-pay prices start at $149 per month for Foundayo and $299 per month for Zepbound, matching the prices available to other self-pay patients. The addition of Foundayo, Lilly's daily oral obesity medicine, also broadens the range of branded weight-loss treatment options available to HIMS customers.
Hims & Hers' weight-loss membership also provides patients with 24/7 access to a care team, nutrition guidance, regular clinical check-ins and access to its weight-loss community. Its technology platform supports provider outreach, treatment planning and follow-up care, enabling the company to maintain engagement throughout the treatment journey.
Importantly, HIMS has confirmed that it has never offered compounded versions of Lilly's GLP-1 medicines and has committed not to do so in the future. Both companies have also agreed to protect independent clinical decision-making, ensuring that providers retain the authority to prescribe treatments they consider appropriate for individual patients. These commitments strengthen the framework for the collaboration while supporting access to FDA-approved medicines through HIMS' digital care platform.
Industry Prospects Favoring the Market
According to Grand View Research, the global obesity treatment market size was valued at $15.9 billion in 2024 and is projected to grow from $29 billion in 2026 to $60.5 billion by 2030, at a CAGR of 22.3%.
The industry is driven by several key factors, including the rising global prevalence of obesity and its associated comorbidities, such as diabetes, cardiovascular diseases, and hypertension.
Other News
Recently, Hims & Hers exited the third quarter of 2026 with lower-than-expected earnings and revenues. Nevertheless, the company recorded robust year-over-year revenue growth, supported by strong performances across its domestic and international businesses. The increase in subscribers and monthly revenue per average subscriber during the quarter was encouraging.
Per management, HIMS' international performance benefited from the Eucalyptus acquisition, while domestic revenue growth accelerated for the second consecutive quarter. The company's expanding weight loss portfolio, strategic collaborations with Novo Nordisk and Eli Lilly and continued investments in AI-driven technology are encouraging.
Hims & Hers Health, Inc. Price
Hims & Hers Health, Inc. price | Hims & Hers Health, Inc. Quote
HIMS’s Zacks Rank & Key Picks
Currently, HIMS carries a Zacks Rank #4 (Sell).
Some better-ranked stocks from the broader medical space are Glaukos (GKOS - Free Report) and Intuitive Surgical (ISRG - Free Report) .
Glaukos, currently flaunting a Zacks Rank #1 (Strong Buy), reported third-quarter 2026 adjusted earnings per share (EPS) of 47 cents, which surpassed the Zacks Consensus Estimate by 491.7%. Revenues of $211 million beat the Zacks Consensus Estimate by 25%. You can see the complete list of today’s Zacks #1 Rank stocks here.
GKOS has an estimated earnings growth rate of 155.6% for 2026. The company’s earnings beat estimates in three of the trailing four quarters and missed once, the average surprise being 138.6%.
Intuitive Surgical, currently carrying a Zacks Rank #2 (Buy), reported third-quarter 2026 adjusted EPS of $3.00, which beat the Zacks Consensus Estimate by 13.6%. Revenues of $3.05 billion surpassed the Zacks Consensus Estimate by 4.9%.
Intuitive Surgical has a long-term estimated growth rate of 15.5%. ISRG’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 15.1%.